Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab within its marketing authorisation for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer.
Following on from information provided to NICE by the company in June 2021, the appraisal of Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1574

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Timeline

Key events during the development of the guidance:

Date Update
21 November 2022 Following on from information provided to NICE by the company in June 2021, the appraisal of Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
21 November 2022 Discontinued. Following on from information provided to NICE by the company in June 2021, the appraisal of Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
20 August 2021 Suspended. Following a regulatory update from the company we have suspended the appraisal of atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]. The company has withdrawn its application to extend the marketing authorisation in this indication. We will continue to monitor the situation and will provide an update when we have further information.
05 February 2021 Invitation to participate
22 October 2020 - 19 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 February 2020 Please note that following on from advice received from the company this appraisal has now been scheduled into the work programme We anticipate that the appraisal will begin during early February 2021 when we will write to you about how you can get involved.
17 October 2019 In progress. Refered 05/12/2017
30 August 2019 Suspended. To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.

For further information on our processes and methods, please see our CHTE processes and methods manual